- Home
- BHE vs TVTX Comparison
BHE vs TVTX Comparison
Compare BHE & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- TVTX
- Stock Information
- Founded
- BHE 1979
- TVTX 2008
- Country
- BHE United States
- TVTX United States
- Employees
- BHE N/A
- TVTX N/A
- Industry
- BHE Electrical Products
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- BHE Technology
- TVTX Health Care
- Exchange
- BHE Nasdaq
- TVTX Nasdaq
- Market Cap
- BHE 1.3B
- TVTX 1.4B
- IPO Year
- BHE 1990
- TVTX N/A
- Fundamental
- Price
- BHE $39.00
- TVTX $15.12
- Analyst Decision
- BHE Strong Buy
- TVTX Strong Buy
- Analyst Count
- BHE 2
- TVTX 15
- Target Price
- BHE $47.00
- TVTX $33.57
- AVG Volume (30 Days)
- BHE 281.7K
- TVTX 1.6M
- Earning Date
- BHE 07-29-2025
- TVTX 07-31-2025
- Dividend Yield
- BHE 1.73%
- TVTX N/A
- EPS Growth
- BHE N/A
- TVTX N/A
- EPS
- BHE 1.44
- TVTX N/A
- Revenue
- BHE $2,612,294,000.00
- TVTX $273,533,000.00
- Revenue This Year
- BHE $0.52
- TVTX $73.84
- Revenue Next Year
- BHE $8.50
- TVTX $46.72
- P/E Ratio
- BHE $27.25
- TVTX N/A
- Revenue Growth
- BHE N/A
- TVTX 75.65
- 52 Week Low
- BHE $30.73
- TVTX $7.72
- 52 Week High
- BHE $52.57
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- BHE 63.84
- TVTX 44.23
- Support Level
- BHE $36.65
- TVTX $13.97
- Resistance Level
- BHE $39.46
- TVTX $15.30
- Average True Range (ATR)
- BHE 0.80
- TVTX 0.71
- MACD
- BHE 0.10
- TVTX 0.16
- Stochastic Oscillator
- BHE 97.51
- TVTX 60.12
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.